Company Overview and News

0
DNO Picks Up Peshkabir Production in Kurdistan

1h globenewswire
Oslo, 17 July 2018 - DNO ASA, the Norwegian oil and gas operator, today announced a two-thirds increase in production from the Peshkabir field in the Tawke license in the Kurdistan region of Iraq to 25,000 barrels of oil per day (bopd) following completion of the Peshkabir-4 well testing program.
GEGYF GEGYY DTNOY GENL DTNOF

0
Genel Energy (GEGYY) Presents At Mena Macro, Credit & Equity Conference - Slideshow

2018-06-28 seekingalpha
The following slide deck was published by Genel Energy PLC ADR in conjunction with this event.
GEGYF GEGYY GENL

0
[Press] DNO Reports Payment for Tawke Deliveries

2018-06-20 oilvoice
Oslo, 20 June 2018 - DNO ASA, the Norwegian oil and gas operator, today reported receipt of USD 62.19 million as payment for March 2018 crude oil deliveries to the export market from the Tawke license in the Kurdistan region of Iraq. The funds will be shared by DNO and partner Genel Energy plc pro-rata to the companies' interests in the license.
GEGYF GEGYY DTNOY GENL DTNOF

0
DNO Reports Payment for Tawke Deliveries

2018-06-20 globenewswire
Oslo, 20 June 2018 - DNO ASA, the Norwegian oil and gas operator, today reported receipt of USD 62.19 million as payment for March 2018 crude oil deliveries to the export market from the Tawke license in the Kurdistan region of Iraq. The funds will be shared by DNO and partner Genel Energy plc pro-rata to the companies' interests in the license.
GEGYF GEGYY DTNOY GENL DTNOF

0
[Press] Genel Energy: Update on Tawke PSC

2018-04-27 oilvoice
Genel Energy plc ('Genel') notes that DNO ASA, as operator of the Tawke PSC (Genel 25% working interest), has today issued the following update on licence activity.
GEGYF GEGYY DTNOY GENL DTNOF

0
[Opinion] Oil Price, Jersey Oil & Gas, Genel Energy

2018-04-27 oilvoice
Oil Price A very short blog, I am out of my office and running on borrowed internet time. Oil was up yesterday and again today, after all the French kissing Macron went and ruined it all by saying something stupid like, I dont really like what you stand for Mr President. The stuff about I Ran went down like the proverbial and Donald is likely to go his own way to keep the musical analogy going, accordingly geopolitics continues to dominate the short term oil price.
GEGYF SDRYF GEGYY ZEE RKH GENL SAVP SVNNF RCKHF CANIF

0
[Press] Sterling Energy: IMS

2018-04-25 oilvoice
Sterling Energy plc (the ‘Company' or 'Sterling') together with its subsidiary undertakings (the ‘Group') is today issuing its Interim Management Statement and financial results for the first quarter ended 31 March 2018. All figures are unaudited unless stated otherwise.
SEY GEGYF GEGYY GENL

0
[Press] Genel Energy: Report on Payments to Governments

2018-04-12 oilvoice
This report sets out details of the payments made to governments by Genel Energy plc and its subsidiary undertakings ("Genel") for the year ended 31 December 2017 as required under the Disclosure and Transparency Rules of the UK Financial Conduct Authority (the 'DTRs') and in accordance with our interpretation of the Industry Guidance issued for the UK's Report on Payments to Governments Regulations 2014, as amended in December 2015 ('the Regulations').
GEGYF GEGYY GENL

0
Genel Energy PLC 2017 Q4 - Results - Earnings Call Slides

2018-03-26 seekingalpha
The following slide deck was published by Genel Energy PLC in conjunction with their 2017 Q4 earnings call.
GEGYF GEGYY GENL

12
[Opinion] Saffron/Coro, Range Resources, Genel Energy, SDX Energy

2018-03-23 oilvoice
Saffron has announced today that James Menzies is to join as CEO with effect from the first of May. James was founder of Salamander Energy, later taken over by Ophir Energy in a transaction worth $850m in 2015. Menzies will join the board with Sara Edmonson as Deputy Chief Executive and will lead the process of building the business in SE Asia where I am sure a number of opportunities are well advanced.
OPHR RRC GEGYF SDRYF GEGYY RGRYY GENL RRL RRS RGRLF

25
Genel Energy's (GEGYF) CEO Murat Özgül on Q4 2017 Results - Earnings Call Transcript

2018-03-23 seekingalpha
Good morning, ladies and gentlemen. I am Murat Özgül, CEO of Genel Energy and I would like to welcome you to our 2017 full-year results presentation. It has been a fantastic year for Genel, and there are significant opportunities ahead. Today, I'm joined by Esa, our Chief Financial Officer and Bill, our Chief Operating Officer. Our Chairman, Steve and members other members of the executive committee and senior management are also here in the audience.
BHI GEGYF GEGYY GENL

0
[Press] Genel Energy plc: Audited Results for the Year Ended 31 December 2017

2018-03-22 oilvoice
Genel Energy plc ('Genel' or 'the Company') announces its audited results for the year ended 31 December 2017.
GEGYF GEGYY GENL

0
Genel Energy back in profit as Kurdish oil payments flow

2018-03-22 telegraph.co.uk
Genel Energy has emerged from years of struggle in war-torn Kurdistan to stage a decisive return to profit despite producing less oil.
GEGYF GEGYY GENL

0
DNO Reports Payment for Tawke Deliveries

2018-03-22 globenewswire
Oslo, 22 March 2018 - DNO ASA, the Norwegian oil and gas operator, today reported receipt of USD 62.46 million from the Kurdistan Regional Government as payment for December 2017 crude oil deliveries to the export market from the Tawke license. The funds will be shared by DNO and partner Genel Energy plc pro-rata to the companies' interests in the license.
GEGYF GEGYY DTNOY GENL DTNOF

38
Market report: Oil price surge drives FTSE recovery

2018-03-20 telegraph.co.uk
Oil prices leapt to a six-week high on hopes that the White House will ramp up the pressure on Iran’s output by reimposing sanctions and offset a surge in US supply that is threatening to tip the fragile balance of the market.
JSTLF GEGYF NTRSP MS.PRE MS.PRF AMFW MS.PRG RDSB RDSA WG MS.PRA NTRS MS RYDAF JSTTY RDS.B RDS.A JE GENL AMFW GEGYY MS.PRI MS.PRK AMCBF RYDBF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

34m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 00B55Q3P3